The Economic Burden of Gastrointestinal Stromal Tumor (GIST) Recurrence in Patients Who Have Received Adjuvant Imatinib Therapy
Journal of Medical Economics - United Kingdom
doi 10.3111/13696998.2014.991787
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 5, 2014
Authors
Publisher
Informa Healthcare